Overview

Cytyc Corporation is a diversified women's health company that designs, develops, manufactures, and markets innovative and clinically effective products. Cytyc products cover a range of women's health applications, including cervical cancer screening, treatment of excessive menstrual bleeding, radiation treatment of early-stage breast cancer and breast cancer risk assessment.

Cytyc operates its business in three segments: domestic diagnostic products, domestic surgical products, and international.

The domestic diagnostic products segment develops and markets the ThinPrep System^® in the United States. The ThinPrep System is the most widely used method for cervical cancer screening in the United States primarily for use in cytology testing applications focused on women's health, such as cervical cancer screening.

Cytyc's domestic surgical products segment manufactures and markets the NovaSure^® System, an innovative endometrial ablation device to treat menorrhagia, or excessive menstrual bleeding; and the MammoSite^® Radiation Therapy System, a device for the treatment of breast cancer that positions radiation sources directly into the post-lumpectomy site to optimize radiation treatment delivery while minimizing damage to healthy tissue. The domestic surgical products segment markets these products in the United States.

The international segment markets diagnostic and surgical products outside of the United States with a presence in Europe, Asia, Canada, and Australia.